Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163617 · ClinicalTrials.gov registry record · Phase 2
The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01163617: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01163617 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01163617, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to administer adalimumab.
Primary Outcome
Participant's overall satisfaction of the injection was collected on a 10-cm visual analog scale (VAS) completed by participants immediately after self-injection. 0 = extremely unsatisfied, 10 = extremely satisfied.
Interventions
- DEVICE Adalimumab delivered in current syringe
- DEVICE Adalimumab delivered in Physiolis syringe
- DEVICE Adalimumab delivered in current autoinjector
- DEVICE Adalimumab delivered in Physiolis autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT01163617 record still lists
NCT01163617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 4 interventions - of which Adalimumab delivered in current syringe is the first listed.
NCT01163617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01163617 about?
NCT01163617 is a clinical study titled "The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients". This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to administer adalimumab.
What is the current status of trial NCT01163617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01163617?
The interventions under investigation include: Adalimumab delivered in current syringe (DEVICE), Adalimumab delivered in Physiolis syringe (DEVICE), Adalimumab delivered in current autoinjector (DEVICE), Adalimumab delivered in Physiolis autoinjector (DEVICE).
Who is sponsoring clinical trial NCT01163617?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01163617's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia